Arbekacin

In response to the clinical treatment dilemma of multidrug-resistant Gram-negative bacterial infections, the iterative upgrade of aminoglycoside antibiotics has become an important breakthrough direction. As a new generation of semi-synthetic aminoglycoside drugs, arbekacin effectively avoids the destruction of most aminoglycoside-inactivating enzymes by modifying the chemical structure of kanamycin B, and maintains strong antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), gentamicin-resistant Pseudomonas aeruginosa, Enterobacteriaceae bacteria, etc. Its mechanism of action is to target the 30S subunit of bacterial ribosomes to inhibit protein synthesis. Clinically, it is mainly used for moderate to severe infections such as sepsis, pneumonia and urinary tract infection caused by susceptible bacteria, especially suitable for patients with drug-resistant bacterial infections who do not respond to other antibacterial drugs, providing a key treatment option in the field of severe infections.

At present, the global market size of aminoglycoside antibiotics exceeds US$2 billion, among which the annual compound growth rate of new drug-resistant varieties remains at around 7%. As a high-end variety among them, the market of arbekacin is mainly concentrated in East Asia, with Japan and China as the core consumer markets. The domestic market has not yet formed large-scale commercial application, and the existing clinical demand mainly relies on imported raw materials and preparations. With the annual increase in the incidence of drug-resistant bacterial infections, the market expansion space will be significant after the accessibility is improved in the future. (Note: There is no publicly verifiable data on the segmented market size and share of arbekacin at present.)

The original research enterprise of arbekacin is Meiji Seika Pharma Co., Ltd. of Japan, and the original brand name is "Habekacin". The expiration date of its core compound patent in Japan is 2002, and the patents in other major markets have all expired. The main dosage forms approved by the original manufacturer are injections, with specifications of 50mg/1mL and 100mg/2mL. The original injection has been included in the Japanese Reference Listed Drug Catalogue, but has not yet been included in the Chinese Catalogue of Chemical Drugs. As of the retrieval time point, no valid registration number (status A) of arbekacin API has been found on the platform of the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China, and there is no arbekacin preparation variety approved for marketing in China. (Data as of October 2024, please refer to the official website of CDE for the latest information.)

CATO can provide a full set of arbekacin impurity reference standards, which can fully cover the whole process requirements in the R&D process, including structure identification, qualitative and quantitative analysis of impurities, stability studies, etc. Most impurity reference standards are kept in regular stock. For in-stock products, orders placed before 16:00 can be shipped on the same day. All products meet the quality requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can provide reliable material basis support for the R&D and registration declaration of related APIs and preparations.